SAN DIEGO, April 24, 2006 /PRNewswire-FirstCall via COMTEX News Network/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD) announced today the filing of a preliminary prospectussupplement to its effective shelf registration statement previously filed withthe Securities and Exchange Commission relating to a proposed underwrittenpublic offering of $75 million of its common stock. In connection with theoffering, ACADIA also plans to grant the underwriters an option to purchaseapproximately $11 million of additional shares of its common stock. All ofthe shares are being sold by ACADIA.
The book-running managers for the offering are Banc of America SecuritiesLLC and Lehman Brothers Inc. and the co-managers are Piper Jaffray & Co., JMPSecurities LLC and Canaccord Adams Inc.
These securities may not be sold nor may offers to buy be accepted priorto the time the final prospectus supplement has been filed. This pressrelease shall not constitute an offer to sell or the solicitation of an offerto buy these securities, nor shall there be any sale of these securities, inany jurisdiction in which such offer, solicitation or sale would be unlawfulprior to registration or qualification under the securities laws of any suchjurisdiction. The offering of these securities may be made only by means ofthe final prospectus supplement and related prospectus relating to theoffering. You may obtain a preliminary prospectus supplement and prospectusby contacting Banc of America Securities LLC, Capital Markets (ProspectusFulfillment) by e-mail to dg.prospectus_distribution@bofasecurities.com or bymail to Banc of America Securities LLC, Capital Markets Operations, 100 West33rd Street, 3rd Floor, New York, NY 10001 and Lehman Brothers Inc. by emailto monica_castillo@adp.com or by fax to (631) 254-7268 or by mail to LehmanBrothers, c/o ADP Financial Services, Prospectus Fulfillment, 1155 Long IslandAvenue, Edgewood, NY 11717.
ACADIA Pharmaceuticals is a biopharmaceutical company with its corporateheadquarters located in San Diego, California and research and developmentoperations in both San Diego and Malmo, Sweden.
Lisa Barthelemy, Director, Investor Relations, or Thomas H. Aasen, Vice President andChief Financial Officer, +1-858-558-2871, both of ACADIA Pharmaceuticals Inc.